Gilead Sciences (NASDAQ:GILD) has submitted a marketing application to the FDA seeking approval of filgotinib for patients with moderate-to-severe rheumatoid arthritis.
It filed the application with a Priority Review Voucher which, if the agency accepts it, shortens the review clock to six months.
The company is co-developing and co-commercializing the JAK1 inhibitor with Galapagos NV (NASDAQ:GLPG) under a 2015 agreement. The filing triggers a $20M milestone payment to GLPG.
Gilead Sciences (NASDAQ:GILD) has submitted a marketing application to the FDA seeking approval of filgotinib for patients with moderate-to-severe rheumatoid arthritis.
It filed the application with a Priority Review Voucher which, if the agency accepts it, shortens the review clock to six months.
The company is co-developing and co-commercializing the JAK1 inhibitor with Galapagos NV (NASDAQ:GLPG) under a 2015 agreement. The filing triggers a $20M milestone payment to GLPG.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.